Molecularly-targeted radiation (MTR) against PSMA is coming and good to see this technology getting traction. @Telixpharma is committed to moving the field by providing PSMA imaging technology for the $ECYT US Phase III trial.
https://t.co/WJD6MzuRyW
Home
Latest News
Telix Pharmaceuticals Selects Goodwin Biotechnology as Manufacturing Scale‐up Partner
Telix has selected Goodwin Biotechnology, Inc. to optimize the process for cGMP manufacturing of our renal...Read More
May 3, 2018
Australia’s Telix forges global partnerships to harness power of radiopharmaceuticals (BioWorld)
The 29:81 (April 2018) edition edition of BioWorld has a very nice little write up on Telix...Read More
May 1, 2018
Load More...